News for Healthier Living

Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026

The improved overall survival in patients with high expression of PI3K-gamma in this Phase 1 study is internally consistent with the observed responses and is externally validated by the TCGA database, which suggests a poor prognosis for patients with high expression of PI3K-gamma. Eganelisib generated a striking efficacy signal while demonstrating a favorable safety and tolerability profile in this Phase 1 study.

June 2, 2026


June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026

May 22 2026

May 21 2026

May 20 2026

May 19 2026